Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation.

Abstract:

:This study was undertaken to evaluate the toxicity and pharmacokinetics of a dimethyl sulphoxide (DMSO)-based intravenous formulation of busulphan in the conditioning of 45 patients undergoing allogeneic or autologous stem cell transplantation (SCT). Busulphan was given as a single daily dose. In 15 patients a single dose of intravenous busulphan, given over 3 h in 1 d, was combined with additional oral (single daily) doses. Thirty patients received all four daily doses intravenously. Busulphan plasma levels were analysed using high performance liquid chromatography. There was no major acute toxicity with daily intravenous doses of 2.8-3.1 mg/kg infused over 3 h. No veno-occlusive disease (VOD) was seen in 30 patients receiving busulphan as an intravenous formulation over 4 d. In the group of 15 patients receiving three oral doses and one intravenous single daily dose, one patient experienced mild VOD. Pharmacokinetic samples were taken over at least 2 d of treatment in 44 patients. The area under the concentration time curve (AUC) values normalized for a dose of 1 mg/kg were 7000 ng/ml x h on d 1 and 5890 ng/ml x h on d 4, thus showing a moderate decrease over time. This was accompanied by a moderate increase of the clearance from 2.6 to 3.0 ml/min/kg. Administration of busulphan as a DMSO-based intravenous formulation was well tolerated. The total dose of busulphan can be given in four (rather than the typical 16) doses. With such a regimen, the intravenous administration becomes feasible on an outpatient basis.

journal_name

Br J Haematol

authors

Schuler US,Renner UD,Kroschinsky F,Johne C,Jenke A,Naumann R,Bornhäuser M,Deeg HJ,Ehninger G

doi

10.1046/j.1365-2141.2001.03044.x

subject

Has Abstract

pub_date

2001-09-01 00:00:00

pages

944-50

issue

4

eissn

0007-1048

issn

1365-2141

pii

bjh3044

journal_volume

114

pub_type

杂志文章
  • Paediatric B-cell precursor acute lymphoblastic leukaemia with t(1;19)(q23;p13): clinical and cytogenetic characteristics of 47 cases from the Nordic countries treated according to NOPHO protocols.

    abstract::The translocation t(1;19)(q23;p13)/der(19)t(1;19) is a risk stratifying aberration in childhood B-cell precursor acute lymphoblastic leukaemia (BCP ALL) in the Nordic countries. We have identified 47 children/adolescents with t(1;19)/der(19)t(1;19)-positive BCP ALL treated on two successive Nordic Society of Paediatri...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.2011.08824.x

    authors: Andersen MK,Autio K,Barbany G,Borgström G,Cavelier L,Golovleva I,Heim S,Heinonen K,Hovland R,Johannsson JH,Johansson B,Kjeldsen E,Nordgren A,Palmqvist L,Forestier E

    更新日期:2011-10-01 00:00:00

  • In vitro efficacy of l-asparaginase in childhood acute myeloid leukaemia.

    abstract::To explore the potential efficacy of l-asparaginase treatment in acute myeloid leukaemia (AML) patients, we studied the in vitro resistance of French-American-British (FAB) subtypes of childhood AML to l-asparaginase using a methyl-thiazol-tetrazolium assay. We tested leukaemic cells obtained from 177 common acute lym...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1046/j.1365-2141.2003.04703.x

    authors: Okada S,Hongo T,Yamada S,Watanabe C,Fujii Y,Ohzeki T,Horikoshi Y,Ito T,Yazaki M,Komada Y,Tawa A

    更新日期:2003-12-01 00:00:00

  • Elevated urinary levels of thromboxane and prostacyclin metabolities in sickle cell disease reflects activated platelets in the circulation.

    abstract::There is evidence for increased factor VII turnover and the associated increased thrombin generation and fibrinolytic activities in sickle cell disease (SCD) that may affect in vivo platelet and endothelial cell reactivity. We studied the release of specific eicosanoids that are indicative of in vivo platelet activati...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.1994.tb08316.x

    authors: Kurantsin-Mills J,Ibe BO,Natta CL,Raj JU,Siegel RS,Lessin LS

    更新日期:1994-07-01 00:00:00

  • Platelet-associated complement in chronic ITP.

    abstract::Chronic ITP is due to antibody-induced destruction of platelets by the reticuloendothelial (RE) system. The role of complement in this process is unclear. We measured platelet-associated complement (PAC) components C3, C3bi, C4 and C9 in 16 patients with chronic ITP, in two of these patients prior to and after splenec...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.1985.tb07477.x

    authors: Kurata Y,Curd JG,Tamerius JD,McMillan R

    更新日期:1985-08-01 00:00:00

  • A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.

    abstract::Interleukin-6 (IL6) plays a central role in multiple myeloma pathogenesis and confers resistance to corticosteroid-induced apoptosis. We therefore evaluated the efficacy and safety of siltuximab, an anti-IL6 monoclonal antibody, alone and in combination with dexamethasone, for patients with relapsed or refractory mult...

    journal_title:British journal of haematology

    pub_type: 杂志文章,多中心研究

    doi:10.1111/bjh.12266

    authors: Voorhees PM,Manges RF,Sonneveld P,Jagannath S,Somlo G,Krishnan A,Lentzsch S,Frank RC,Zweegman S,Wijermans PW,Orlowski RZ,Kranenburg B,Hall B,Casneuf T,Qin X,van de Velde H,Xie H,Thomas SK

    更新日期:2013-05-01 00:00:00

  • A new preconditioning regimen with melphalan, busulphan and total body irradiation followed by low-dose immunosuppressant in allogeneic haemopoietic stem cell transplantation.

    abstract::Twenty adult patients with high-risk leukaemia underwent allogeneic haemopoietic stem cell transplantation after melphalan, busulphan and total body irradiation followed by short-term methotrexate and low-dose cyclosporine or tacrolimus. Three patients developed veno-occlusive disease and no patient developed renal dy...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1046/j.1365-2141.1999.01424.x

    authors: Murata M,Nishida T,Haneda M,Kanie T,Taji H,Iida H,Suzuki R,Hamaguchi M,Minami S,Kodera Y

    更新日期:1999-06-01 00:00:00

  • Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma.

    abstract::Proinflammatory cytokines such as interleukin 6 (IL-6), tumour necrosis factor alpha (TNF-alpha) and IL-1beta are considered to be involved in the pathogenesis of multiple myeloma (MM). In the present study, we examined a G/C polymorphism at position -174 in the promoter region of IL-6, a biallelic polymorphism at pos...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1046/j.1365-2141.2000.01963.x

    authors: Zheng C,Huang DR,Bergenbrant S,Sundblad A,Osterborg A,Björkholm M,Holm G,Yi Q

    更新日期:2000-04-01 00:00:00

  • Role of bone marrow-derived mesenchymal stem cell defects in CD8+ CD28- suppressor T-lymphocyte induction in patients with immune thrombocytopenia and associated mechanisms.

    abstract::Many immune dysfunctions participate in immune thrombocytopenia (ITP) pathogenesis, including numeric and functional defects in suppressor T (Ts) cells and immune-regulation abnormalities in mesenchymal stem cells (MSCs). Recent studies showed that MSCs can promote Ts cell differentiation. Thus, we compared the Ts cel...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/bjh.16953

    authors: Li H,Guan Y,Sun B,Dou X,Liu X,Xue F,Fu R,Zhang L,Yang R

    更新日期:2020-07-16 00:00:00

  • Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzyme.

    abstract::We report on the generation and functional characterization of a humanized immunoenzyme comprising a stable humanized single chain Fv (scFv) with grafted specificity of the anti-CD22 murine monoclonal antibody RFB4 and the human ribonuclease angiogenin (ANG). The fusion protein produced from transiently transfected ma...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.2005.05356.x

    authors: Krauss J,Arndt MA,Vu BK,Newton DL,Rybak SM

    更新日期:2005-03-01 00:00:00

  • A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events.

    abstract::Dickkopf-1 (DKK1), expressed by myeloma cells, suppresses osteoblast function and plays a key role in bone disease in multiple myeloma. BHQ880, a human neutralizing IgG1 anti-DKK1 monoclonal antibody, is being investigated for its impact on multiple myeloma-related bone disease and as an agent with potential anti-myel...

    journal_title:British journal of haematology

    pub_type: 杂志文章,多中心研究

    doi:10.1111/bjh.13056

    authors: Iyer SP,Beck JT,Stewart AK,Shah J,Kelly KR,Isaacs R,Bilic S,Sen S,Munshi NC

    更新日期:2014-11-01 00:00:00

  • How we prevent and manage infection in sickle cell disease.

    abstract::Sickle cell disease (SCD) affects approximately 100,000 people in the US, 12,500 in the UK, and millions worldwide. SCD is typified by painful vaso-occlusive episodes, haemolytic anaemia and organ damage. A secondary complication is infection, which can be bacterial, fungal or viral. Universal newborn screening, routi...

    journal_title:British journal of haematology

    pub_type: 杂志文章,评审

    doi:10.1111/bjh.13526

    authors: Sobota A,Sabharwal V,Fonebi G,Steinberg M

    更新日期:2015-09-01 00:00:00

  • Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.

    abstract::Selinexor, an oral Selective Inhibitor of Nuclear Export, targets Exportin 1 (XPO1, also termed CRM1). Non-clinical studies support combining selinexor with proteasome inhibitors (PIs) and corticosteroids to overcome resistance in relapsed/refractory multiple myeloma (RRMM). We conducted a phase I dose-escalation tria...

    journal_title:British journal of haematology

    pub_type: 杂志文章,多中心研究

    doi:10.1111/bjh.15969

    authors: Jakubowiak AJ,Jasielec JK,Rosenbaum CA,Cole CE,Chari A,Mikhael J,Nam J,McIver A,Severson E,Stephens LA,Tinari K,Rosebeck S,Zimmerman TM,Hycner T,Turowski A,Karrison T,Zonder JA

    更新日期:2019-08-01 00:00:00

  • MUC1-C is a target in lenalidomide resistant multiple myeloma.

    abstract::Lenalidomide (LEN) acts directly on multiple myeloma (MM) cells by inducing cereblon-mediated degradation of interferon regulatory factor 4, Ikaros (IKZF)1 and IKZF3, transcription factors that are essential for MM cell survival. The mucin 1 (MUC1) C-terminal transmembrane subunit (MUC1-C) oncoprotein is aberrantly ex...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/bjh.14801

    authors: Yin L,Tagde A,Gali R,Tai YT,Hideshima T,Anderson K,Avigan D,Kufe D

    更新日期:2017-09-01 00:00:00

  • Arsenic trioxide (AT) is a novel human neutrophil pro-apoptotic agent: effects of catalase on AT-induced apoptosis, degradation of cytoskeletal proteins and de novo protein synthesis.

    abstract::The anti-cancer drug arsenic trioxide (AT) induces apoptosis in a variety of transformed or proliferating cells. However, little is known regarding its ability to induce apoptosis in terminally differentiated cells, such as neutrophils. Because neutropenia has been reported in some cancer patients after AT treatment, ...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.2005.05866.x

    authors: Binet F,Cavalli H,Moisan E,Girard D

    更新日期:2006-02-01 00:00:00

  • Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category?

    abstract::Both the 2001 World Health Organisation (WHO) classification of haematopoietic neoplasms and the 2008 WHO classification revision include a distinctive diagnostic category, refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T), to describe those rare patients who have both >or=15% ring sideroblasts and...

    journal_title:British journal of haematology

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2141.2008.07526.x

    authors: Wardrop D,Steensma DP

    更新日期:2009-03-01 00:00:00

  • Lymphotoxin, tumour necrosis factor and interleukin-6 gene transcripts are present in Hodgkin and Reed-Sternberg cells of most Hodgkin's disease cases.

    abstract::Tissue specimens from 26 cases of Hodgkin's disease (HD) and six HD-derived cell lines were analysed for tumour necrosis factor (TNF), lymphotoxin (LT), and interleukin (IL)-6 RNA transcripts by in situ hybridization, in some cases subsequent to immunohistology for CD30 antigen. LT and TNF transcripts were found in tu...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.1993.tb03138.x

    authors: Foss HD,Herbst H,Oelmann E,Samol J,Grebe M,Blankenstein T,Matthes J,Qin ZH,Falini B,Pileri S

    更新日期:1993-08-01 00:00:00

  • LISA: a web-based decision-support system for trial management of childhood acute lymphoblastic leukaemia.

    abstract::Continuation chemotherapy is a key component of the treatment of childhood acute lymphoblastic leukaemia. During this treatment phase, weekly dose adjustments are carried out based on current and historical full blood counts (FBCs). The dose decision pathway is complex and suboptimal therapy may result if information ...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.2005.05541.x

    authors: Bury J,Hurt C,Roy A,Cheesman L,Bradburn M,Cross S,Fox J,Saha V

    更新日期:2005-06-01 00:00:00

  • Abnormal platelet function in Chediak-Higashi syndrome.

    abstract::Platelets in an infant with Chediak-Higashi (C-H) syndrome without bleeding manifestations and not in the accelerated phase showed abnormal function consistent with storage pool disorder as shown by abnormal aggregation, decreased storage capacity and release of [14C]5-HT, low endogenous 5-HT, reduced ATP and ADP with...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.1977.tb00618.x

    authors: Boxer GJ,Holmsen H,Robkin L,Bang NU,Boxer LA,Baehner RL

    更新日期:1977-04-01 00:00:00

  • A novel factor-dependent human myelodysplastic cell line, MDS92, contains haemopoietic cells of several lineages.

    abstract::A novel long-term cultured interleukin (IL)-3-dependent human myelodysplastic cell line, MDS92, was shown to contain several myeloid-lineage cells such as neutrophils, macrophages, eosinophils, and a small number of megakaryocyte-lineage cells. Therefore this cell line possesses at least bipotential characteristics of...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.1995.tb05391.x

    authors: Tohyama K,Tohyama Y,Nakayama T,Ueda T,Nakamura T,Yoshida Y

    更新日期:1995-12-01 00:00:00

  • Quality assessment of immunological marker analysis and the immunological diagnosis in leukaemia and lymphoma: a multi-centre study. Dutch Cooperative Study Group on Immunophenotyping of Leukaemias and Lymphomas (SIHON).

    abstract::In order to standardize and assess the quality of immunophenotyping of leukaemias and lymphomas for diagnostic purposes, a cooperative study group in the Netherlands, SIHON, has formulated guidelines for the composition of antibody panels to be applied and guidelines for the interpretation of the marker analysis. To a...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.1992.tb04558.x

    authors: van't Veer MB,Kluin-Nelemans JC,van der Schoot CE,van Putten WL,Adriaansen HJ,van Wering ER

    更新日期:1992-04-01 00:00:00

  • The management and outcome of chronic graft-versus-host disease.

    abstract::Chronic graft-versus-host disease (cGVHD) is a common complication following allogeneic haematopoietic cell transplantation (HCT). It is the leading cause of non-relapse mortality in transplant survivors and has a significant impact upon their functional status and quality of life. Despite significant advances being m...

    journal_title:British journal of haematology

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2141.2007.06652.x

    authors: Fraser CJ,Scott Baker K

    更新日期:2007-07-01 00:00:00

  • Chronic myeloproliferative disorders: improved platelet aggregation following venesection.

    abstract::Venesection of 10% of whole blood volume or plateletpheresis was performed in nine patients with chronic myeloproliferative disorders and in five normal control subjects. Before venesection, the patients showed impaired platelet aggregation in 33% of tests, most often in response to stimulation with 9 mumol adrenaline...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.1978.tb03629.x

    authors: Boughton BJ

    更新日期:1978-08-01 00:00:00

  • Lymphocyte function after autologous bone marrow transplantation (BMT): a comparison with patients treated with allogeneic BMT and with chemotherapy only.

    abstract::T- and B-cell function after autologous bone marrow transplantation (ABMT) was assessed and compared with that found after allogeneic BMT and after chemotherapy only. In all 16 patients with acute leukaemia in remission treated with high-dose chemotherapy and single or double ABMT, T-helper numbers and function in an ...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.1986.tb07547.x

    authors: Armitage RJ,Goldstone AH,Richards JD,Cawley JC

    更新日期:1986-08-01 00:00:00

  • Analysis of leucocyte differentiation antigens in blood and bone marrow from patients with Waldenström's macroglobulinaemia.

    abstract::Peripheral blood and bone marrow mononuclear cells from 10 patients with newly diagnosed Waldenström's macroglobulinaemia were analysed for the presence of leucocyte differentiation antigens using flow cytometry. Most patients had circulating intracytoplasmic-mu cells that were positive for the B-cell specific antigen...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.1987.tb04139.x

    authors: Kucharska-Pulczynska M,Ellegaard J,Hokland P

    更新日期:1987-04-01 00:00:00

  • Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time.

    abstract::MPLW515L/K and JAK2V617F can co-exist in myelofibrosis with myeloid metaplasia (MMM). The chronology of clonal emergence was studied in three such cases using serially stored bone marrow. At diagnosis, a major MPL515 mutant clone was accompanied by a minor JAK2V617F clone in all three instances. At 25 time points over...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.2006.06348.x

    authors: Lasho TL,Pardanani A,McClure RF,Mesa RA,Levine RL,Gilliland DG,Tefferi A

    更新日期:2006-12-01 00:00:00

  • Myelomatosis and the hyperviscosity syndrome.

    abstract::Eleven patients are described in whom myelomatosis was complicated by the laboratory and clinical features of the hyperviscosity syndrome (HVS). The myeloma type was IgA in nine and IgG3 in two. In those patients with IgA myeloma the HVS was related to the presence of high molecular weight complexes in the serum. Remi...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.1978.tb01077.x

    authors: Preston FE,Cooke KB,Foster ME,Winfield DA,Lee D

    更新日期:1978-04-01 00:00:00

  • Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study.

    abstract::A previous dose-finding study has suggested that romiplostim is effective in patients with refractory aplastic anaemia (AA) and 10 µg/kg once weekly was recommended as a starting dose. In this Phase II/III, multicentre, open-label study, romiplostim was administered subcutaneously at a fixed dose of 10 µg/kg once week...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/bjh.17190

    authors: Jang JH,Tomiyama Y,Miyazaki K,Nagafuji K,Usuki K,Uoshima N,Fujisaki T,Kosugi H,Matsumura I,Sasaki K,Kizaki M,Sawa M,Hidaka M,Kobayashi N,Ichikawa S,Yonemura Y,Enokitani K,Matsuda A,Ozawa K,Mitani K,Lee JW,Nakao

    更新日期:2021-01-01 00:00:00

  • Occurrence of acute leukaemia in myeloproliferative disorders.

    abstract::In a series of 306 cases of myeloproliferative disorders followed over a period of 21 years, 18 cases of well-documented acute leukaemia were encountered. Leukaemias were either acute myeloblastic or myelomonocytic and occurred from 6 months to 20 years after the initial diagnosis. Onset was relatively abrupt and the ...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.1977.tb00661.x

    authors: Rosenthal DS,Moloney WC

    更新日期:1977-07-01 00:00:00

  • von Willebrand factor clearance - biological mechanisms and clinical significance.

    abstract::The mechanisms involved in regulating von Willebrand factor (VWF) clearance remain poorly understood. However recent studies have shown that macrophages play a critical role in regulating the half-life of VWF, and have identified specific lectin (including asialoglycoprotein, macrophage galactose-type lectin, Sigec-5 ...

    journal_title:British journal of haematology

    pub_type: 杂志文章,评审

    doi:10.1111/bjh.15565

    authors: O'Sullivan JM,Ward S,Lavin M,O'Donnell JS

    更新日期:2018-10-01 00:00:00

  • Clinical and biological features of paediatric acute myeloid leukaemia (AML) with primary induction failure in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.

    abstract::The prognosis of paediatric acute myeloid leukaemia (AML) with primary induction failure (PIF) is extremely poor, and effective treatment strategies have not been established. We investigated the clinical and biological features of paediatric AML patients with PIF registered to the Japanese Paediatric Leukaemia/Lympho...

    journal_title:British journal of haematology

    pub_type: 杂志文章,多中心研究

    doi:10.1111/bjh.15799

    authors: Miyamura T,Moritake H,Nakayama H,Tanaka S,Tomizawa D,Shiba N,Saito AM,Tawa A,Shimada A,Iwamoto S,Hayashi Y,Koike T,Horibe K,Manabe A,Mizutani S,Taga T,Adachi S

    更新日期:2019-04-01 00:00:00